Tag: Diffuse large B-cell lymphoma (DLBCL)

1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence Rating Level: 1 (Excellent) Diffuse large B-cell lymphoma (DLBCL) is often curable, but a portion of patients are refractory to, or relapse after, treatment with the current standard of care (rituximab,...
1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence Rating Level: 1 (Excellent) Diffuse large B-cell lymphoma (DLBCL) is often curable, but a portion of patients are refractory to, or relapse after, treatment with the current standard of care (rituximab,...